
这个市场不值得进入,已经进入明显的价格战区,而且正在走向拥挤。 结论很硬:新品可盈利率只有15.38%,但新品里84.62%不赚钱;整体可识别盈利产品只有6.25%,说明这里不是“还能挑机会”的市场,而是“少数差异化产品勉强活下来”的市场。
对大品牌来说,能打进去但不划算;对小品牌来说,基本不该进。 证据很清楚:新品牌只有5个,但真正跑出来的只有BUBBLEDANCE和HIEERBUS各1款盈利新品;老品牌里Manmihealth虽然有1款盈利老款B0CKPCXVDV,月销600、月收入719,400元,但它的新产品全失败,说明老品牌也不是“随便复制就赢”,而是要靠成熟资源硬撑。反过来,GEENOA作为老品牌样本,32个产品0盈利;hungkaturn 3款全亏;很多非盈利款还能卖,像GEENOA的B0DM4V3PKM、B0FF15V7J2利润率只有3.82%和4.69%,这就是典型低毛利内卷。用户预算50万人民币,够做单个SKU启动,但不够改变这个市场的结构性问题,因为真正跑通的新品B0FXQT7ZF9前期投入已到6507.48美元,而且它靠的是可伸缩长柄、强去角质定位、外观差异和功能差异,不是普通跟款能复制的。
These products have successfully captured market share and are profitable. Their design and features are suggested for your investment, based on market competition, saturation, and demand.
Green indicates better success rate, red indicates poorer success rate. If you are a new brand, focus on the left side; if you are an old brand, focus on the right side.
不建议进入,这个市场已经是高风险的价格战区,不适合现在下场。 依据样本,整体可盈利产品只有6.25%,新品可盈利率也只有15.38%,而新品牌新品未盈利率高达77.78%,说明大多数新进入者都在亏;同时,市场里大量产品利润率集中在10%上下,几乎没有给普通卖家留下安全空间。
Alternative solutions may pose a risk to your investment in certain markets.
这个市场不值得进入:新品盈利率只有15.38%,而整体可识别盈利产品仅6.25%,说明这里已经是低利润、强同质化的价格战区。更关键的是,进入市场不到一年的新品牌新品盈利率只有22.22%,但新品牌新品亏损率高达77.78%,加上老品牌新品盈利率为0%,说明不是谁都能赚,只有少数做出明显差异化的产品才能活。
这个市场不值得进入,已经处在明显的价格战和过度拥挤状态。 新品里能看见的盈利空间很窄,且新品牌成功案例极少;要么靠老品牌压制,要么靠更强的产品差异化和更高投入才能勉强打进去。
All products profit ratio distribution, including all products. For products with insufficient sales or missing profit ratio data, they will be categorized into other rows. This distribution included products that cannot determine the release date.
This are the profit ratios of all new products. There are products without sufficient sales, no more than 100pcs in 3 months, or no profit ratio data, or just released. Those will be considered as 'other'
Most profitable products ranked by profit value. Only includes products with positive profitability and active sales, regardless of release date.
![]() | B0CKPCXVDV | Manmihealth | 2023-10-08 | Yes | $11.99 | 600pcs | $7194.0 | 10.66% | $766.89 |
B0FXQT7ZF9 | BUBBLEDANCE | 2025-12-30 | Yes | $16.69 | 200pcs | $3338.0 | 14.01% | $467.66 | |
![]() | B0GD7JXLVC | HIEERBUS | 2025-12-30 | Yes | $13.99 | 50pcs | $699.5 | 11.44% | $80.03 |
Most profitable new products ranked by profit value. Only includes newly released products with positive profitability and active sales.
B0FXQT7ZF9 | BUBBLEDANCE | 2025-12-30 | Yes | $16.69 | 200pcs | $3338.0 | 14.01% | $467.66 | |
![]() | B0GD7JXLVC | HIEERBUS | 2025-12-30 | Yes | $13.99 | 50pcs | $699.5 | 11.44% | $80.03 |
这个市场不值得进入:已是高竞争、明显偏价格战的市场,连新品牌的真实成功都很少,老品牌更是全面失手。 现在看到的唯一正向样本,是 BUBBLEDANCE 的 B0FXQT7ZF9,靠“基于老款做差异化”才跑出来,但这类成功只占新上架里 15.38%,而新品牌新上架失败率高达 77.78%,老品牌新上架成功率则是 0%。
证据很直接:市场里可识别的整体盈利产品只占 6.25%,新品盈利率 15.38%,但新品里 84.62% 仍然不赚钱;按品牌看,GEENOA 是典型老品牌样本,32 个产品 0 盈利,成功率 0%,而它的 4 个新上架全部失败。 热销却不赚钱的信号也很强:Top 非盈利新品里,GEENOA 占了大头,单个产品如 B0DM4V3PKM、B0FF15V7J2 仍然在卖,但毛利只有 3.82% 和 4.69%,这是典型低毛利内卷;整体利润区间也集中在 0%~20%,没有任何 30% 以上的产品,说明市场不是高利润扩张,而是低利润挤压。用户预算 50 万人民币,看起来够启动单个 SKU,但这点预算对这个市场不构成优势,因为 B0FXQT7ZF9 这种看似成功的新品,前期投入已经到 6507.48 美元,而且靠的是明显差异化设计、功能和外观,不是简单铺货能复制。
对大品牌来说,理论上还能用更强品牌力、研发和营销硬进,但这不是高概率机会;对小品牌来说,真实可参考的成功样本几乎没有,且市场里已有“像成功、但更像激进营销”的新品牌痕迹,若没有强差异化、设计创新和额外预算,基本不要进。可跟的正面样本只有 BUBBLEDANCE / B0FXQT7ZF9;要避开的反面样本是 GEENOA 及其一批新上架失败款(如 B0GYWJ7XMD、B0GYWF8158、B0GYWF67KK、B0GZYR9D3Y)。
What is the ratio of profitable products
What is the ratio of different brands owning all profitable new products
What is the ratio of different brands owning all nonprofitable new products
结论很明确:这个市场不值得进入,已经进入高风险价格战区,且正在走向饱和。 近端新品牌里只有少数能赚钱,新进入者成功率低,且最近新增品牌与亏损产品同时出现,说明竞争正在变难,不是变容易。
从数据看,市场里新品牌只有5个,但新发布产品13个;新品牌新发布产品里,盈利率只有15.38%,未盈利占77.78%。更关键的是,最近一批新品牌里,BUBBLEDANCE 的 B0FXQT7ZF9 只有一个盈利款,毛利率约14.01%,月销200、月收入333,800元,但 HIEERBUS 的 B0GD7JXLVC 虽然毛利约11.44%,仍只有50单/月,而同品牌另外两款 B0GD7F4BG7、B0GD7G9CCT 都亏损;hungkaturn 的 B0GVTFP37F、B0GVTFLZGB、B0GYSD8WXD 也全部亏损,且其中 B0GVTFLZGB 标出约15.83%的毛利却仍卖不动,说明不是单纯“有利润就能活”,而是需要更强的投放和打法。按你给的规则,最近新入场并没有形成可复制的真实小品牌成功路径,反而有明显的营销驱动和高失败率信号;再加上当前整体可识别盈利产品仅6.25%,这就是典型的高风险、低容错、价格竞争激烈市场。
对大品牌和小品牌都不友好:大品牌如果硬进,至少要跟上 Manmihealth 这类老品牌的体量,Manmihealth 旧款 B0CKPCXVDV 月销600、月收入719,400元,且长期积累了1217个评价;小品牌则没有真正的低评价高成功样本可抄,近期所谓“成功”也只是 BUBBLEDANCE、HIEERBUS 这类新品牌里的少数款,而且都带有较高投放和试错成本。不建议继续推进。 如果一定要做,只能把 Manmihealth 的成熟款 B0CKPCXVDV 和新品牌里唯一赚钱的 B0FXQT7ZF9、B0GD7JXLVC 作为对照,但这不是好机会,而是高成本硬打市场。
Y-axis is product counts. X-axis is time period. For each time period, there are 2 column, each column is a released type of a product. Columns are in following orders: New product, New product on old listing
Y-axis is product counts. X-axis is time period. For each time period, there are 2 column, each column is a released type of a product. Columns are in following orders: New product, New product on old listing
Header is the profit ratios and first column is different time period. Each cells includes how many products are relased at the specific timerange and has a corresponding profit ratios. Only profitable and with active sales (more than 100 pcs in 3 months) will be considered. Any products without sufficient sold units in 3 months will be marked as 'other'.
| Time/Profit% | x < -10.0% | -10.0% <= x < 0.0% | 0.0% <= x < 10.0% | 10.0% <= x < 20.0% | 20.0% <= x < 30.0% | 30.0% <= x < 40.0% | x >= 40.0% | other |
|---|---|---|---|---|---|---|---|---|
| 2022 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2023 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2024 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 3 |
| 2026 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 |
Header is the profit ratios and first column is different time period. Each cells includes how many products are relased at the specific timerange and has a corresponding profit ratios. Only profitable and with active sales (more than 100 pcs in 3 months) will be considered. Any products without sufficient sold units in 3 months will be marked as 'other'.
| Time/Profit% | x < -10.0% | -10.0% <= x < 0.0% | 0.0% <= x < 10.0% | 10.0% <= x < 20.0% | 20.0% <= x < 30.0% | 30.0% <= x < 40.0% | x >= 40.0% | other |
|---|---|---|---|---|---|---|---|---|
| 2025/7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025/8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025/9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025/10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025/11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025/12 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 3 |
| 2026/1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 |
| 2026/5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| 2026/6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |